Walleye Capital LLC reduced its position in RAPT Therapeutics, Inc. (NASDAQ:RAPT – Get Rating) by 41.9% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 38,320 shares of the company’s stock after selling 27,681 shares during the quarter. Walleye Capital LLC owned approximately 0.13% of RAPT Therapeutics worth $699,000 as of its most recent SEC filing.
Other institutional investors also recently bought and sold shares of the company. Amalgamated Bank acquired a new position in RAPT Therapeutics in the 1st quarter valued at about $76,000. Dupont Capital Management Corp grew its position in RAPT Therapeutics by 37.8% in the 1st quarter. Dupont Capital Management Corp now owns 7,836 shares of the company’s stock valued at $172,000 after acquiring an additional 2,148 shares in the last quarter. DekaBank Deutsche Girozentrale grew its position in RAPT Therapeutics by 9.8% in the 1st quarter. DekaBank Deutsche Girozentrale now owns 9,000 shares of the company’s stock valued at $196,000 after acquiring an additional 800 shares in the last quarter. MetLife Investment Management LLC grew its position in RAPT Therapeutics by 58.5% in the 1st quarter. MetLife Investment Management LLC now owns 11,028 shares of the company’s stock valued at $243,000 after acquiring an additional 4,070 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its position in RAPT Therapeutics by 23.7% in the 1st quarter. JPMorgan Chase & Co. now owns 13,575 shares of the company’s stock valued at $299,000 after acquiring an additional 2,599 shares in the last quarter. 98.42% of the stock is owned by institutional investors and hedge funds.
RAPT Therapeutics Stock Down 5.9 %
Shares of RAPT opened at $22.75 on Tuesday. The stock has a 50 day moving average price of $22.90 and a 200 day moving average price of $20.48. RAPT Therapeutics, Inc. has a 52-week low of $9.85 and a 52-week high of $40.74.
Insider Activity at RAPT Therapeutics
Wall Street Analyst Weigh In
Several research firms have weighed in on RAPT. Piper Sandler lifted their target price on RAPT Therapeutics from $30.00 to $34.00 and gave the company an “overweight” rating in a research report on Thursday, November 10th. Capital One Financial initiated coverage on RAPT Therapeutics in a research report on Wednesday, September 21st. They set an “overweight” rating and a $48.00 price objective for the company. SVB Leerink lowered their price objective on RAPT Therapeutics from $49.00 to $48.00 and set an “outperform” rating for the company in a research report on Thursday, August 11th. Finally, HC Wainwright lowered their price objective on RAPT Therapeutics from $53.00 to $50.00 and set a “buy” rating for the company in a research report on Monday. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $50.57.
RAPT Therapeutics Company Profile
RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
- Get a free copy of the StockNews.com research report on RAPT Therapeutics (RAPT)
- Wayfair Still Has Its Fair Share of Issues
- This Mid-Cap Tech Stock Embodies Diversified Growth
- Take Two Interactive Software Stock is Taking One Step Back
- Why did NIO take a $581.11 million loss last quarter?
- Is It Time To Take A Ride With Joby Aviation’s EV Innovations?
Receive News & Ratings for RAPT Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RAPT Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.